-

Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2025

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2025 of $1.30 per share on the company’s common stock. The dividend is payable on December 9, 2025 to shareholders of record at the close of business on November 25, 2025. The ex-dividend date is November 25, 2025.

About Johnson & Johnson

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/.

Contacts

Media contact:
media-relations@its.jnj.com

Investor contact:
investor-relations@its.jnj.com

Industry:

Johnson & Johnson

NYSE:JNJ
Release Summary
Q4 dividend
Release Versions
English

Contacts

Media contact:
media-relations@its.jnj.com

Investor contact:
investor-relations@its.jnj.com

More News From Johnson & Johnson

Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced the successful completion of its acquisition of Firefly Bio, Inc., a biotechnology company advancing its proprietary Firelink™ degrader antibody conjugate (DAC) platform, for $1 billion in cash. The Firelink™ DAC platform expands Johnson & Johnson’s oncology portfolio and advances its ambition to develop targeted therapies for some of the most prevalent and difficult-to-treat solid tumors, including KRAS...

Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson1 (NYSE: JNJ) today announced strategic agreements and collaboration with Sail Biomedicines (Sail), a biotechnology company developing in vivo CAR-T therapies for immune-mediated diseases. Johnson & Johnson will collaborate with Sail to advance its lead immune-mediated disease program and broader platform technology, with incentives to expand the application of Sail's in vivo CAR-T platform across additional therapeutic targets over...

Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the "Company") today announced that it has reached an agreement for a comprehensive resolution of the remaining talc litigation with the plaintiff firms leading the federal Multi-District Litigation (MDL) and related state court proceedings, conditioned on, among other things, the express participation of at least 95% of the remaining claims. The proposed resolution follows a favorable ruling by the MDL court, and acknowle...
Back to Newsroom